Pfizer, Teva Settle Patent Litigation on Viagra - - BioPharm International

ADVERTISEMENT

Pfizer, Teva Settle Patent Litigation on Viagra



Pfizer has settled its litigation against Teva Pharmaceuticals USA Inc., relating to Pfizer’s patent covering the use of Pfizer's Viagra (sildenafil citrate) to treat erectile dysfunction in 25-, 50-, and 100-mg tablets. The patent expires in April 2020, including pediatric exclusivity.  As a result of the settlement, Teva will be allowed to launch a generic version of Viagra under a royalty-bearing license on Dec. 11, 2017, in the United States on December 11, 2017, or earlier under certain circumstances. Teva will pay Pfizer a royalty for a license to produce its generic version.  The terms of the settlement agreement are otherwise confidential.  Teva has received tentative approval from FDA for its generic version of Viagra.  

Sources: Pfizer and Teva Pharmaceuticals

blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

GSK Submits EU Regulatory Filing for Malaria Vaccine Candidate
July 29, 2014
Bristol-Myers Squibb and Ono Pharmaceutical Collaborate on Immunotherapies
July 28, 2014
FDA Accepts First Biosimilar Filing
July 24, 2014
Compounding Pharmacy Issues Recall, But Challenges FDA Decision
July 22, 2014
AbbVie's Acquisition of Shire Could Save $8 Billion in Taxes
July 21, 2014
Author Guidelines

Click here